Munich, Germany - November 28th, 2023 - Japanese text
Hiroto Bando assumes this new role in addition to his current leadership positions at Minaris. He has served as General Manager, Regenerative Medicine Business Unit of Resonac Corporation, since January 2022. He also holds the positions of President and CEO of Minaris Regenerative Medicine Co., Ltd. (Japan) and Minaris Regenerative Medicine, LLC (United States). This unified leadership will strengthen Minaris as a global organization. Day-to-day operations at the European facilities will continue to be led by Renate Sporrer, Chief Operating Officer, Minaris Regenerative Medicine GmbH.
“I look forward to working closely with Renate and to strengthening collaboration between our three global regions. In Europe, we are particularly excited about our recent expansion to add a new facility in Munich, Germany. The new manufacturing site will provide additional clean room capacity for cell and gene therapies beginning in 2024,” said Hiroto Bando.
In the position of CEO of the European operations, Hiroto will replace Dusan Kosijer who has served as CEO for the region since January 2021 and prior to that as Chief Financial Officer of Minaris Regenerative Medicine GmbH since 2016. From 2020 to 2022, he also served as Global Chief Financial Officer for the Regenerative Medicine Business Unit of Resonac Corporation.
“I would like to express my deepest gratitude to Dusan, who has been instrumental in guiding our European operations for a significant period. It is through his dedication and efforts that the region has achieved its current standing,” said Hiroto Bando.
About Minaris Regenerative Medicine
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply life-changing therapies to patients globally. Minaris Regenerative Medicine is part of the Resonac Group.
For more information, please visit www.rm.minaris.com
Contact
Dr. Luc St-Onge
Global Head of Sales and Marketing
Minaris Regenerative Medicine GmbH
E-Mail: press@rm.minaris.de
Phone: +49 (0)89 700 9608-0
*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.
